Two of the largest life science companies in the Washington, D.C. area are teaming up to get another COVID-19 vaccine to market.
Gaithersburg-based Emergent BioSolutions (NYSE: EBS) and AstraZeneca (which has its massive campus in Gaithersburg as well) are working towards manufacturing AZD1222, AstraZeneca’s COVID-19 vaccine candidate that is currently undergoing clinical trials.
AstraZeneca went the route of using a weakened adenovirus that contains the genetic material of COVID-19 to create a vaccine. The research is being done in conjunction with Oxford University’s Jenner institute. AstraZeneca largest U.S. location is in Gaithersburg and is the company’s primary biologics research and development arm as well as the home to its Global Medicines Development function and Specialty Products Group.
Emergent would be the manufacturer of the vaccine under a contract worth $87 million.
This is a another big win for Emergent. The company has received several contracts only in the past couple of months to manufacture vaccines for other organizations including one from Johnson & Johnson to produce their COVID-19 vaccine and another from fellow neighbor, Gaithersburg-based Novavax (NASDAQ: NVAX).
One of the biggest it received was a $628 million Federal Government contract to add to the U.S. Strategic National Stockpile.
According to Emergent development services will be provided out of their Gaithersburg product development facility, while large-scale manufacturing of drug substances will be completed at its Baltimore Bayview facility.